Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kg

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uremic Pruritus

Conditions

Uremic Pruritus

Trial Timeline

Aug 10, 2020 → Oct 28, 2021

NCT ID

NCT04470154

About Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kg

Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kg is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Uremic Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT04470154. Target conditions include Uremic Pruritus.

What happened to similar drugs?

0 of 7 similar drugs in Uremic Pruritus were approved

Approved (0) Terminated (0) Active (7)

🔄CrovalimabChugai PharmaceuticalPhase 3

🔄EculizumabAstraZenecaPhase 3

🔄IptacopanNovartisPhase 3

🔄Iptcaopan 200 mgNovartisPhase 3

🔄IptacopanNovartisPhase 3

🔄MR13A9 + PlaceboKissei PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04470154	Phase 2	Completed	Aug 10, 2020	Oct 28, 2021	Uremic Pruritus

Competing Products

15 competing products in Uremic Pruritus

See all competitors

Product	Company	Stage	Hype Score
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Ravulizumab	AstraZeneca	Pre-clinical	33
Eculizumab	AstraZeneca	Phase 3	40
Iptacopan	Novartis	Phase 3	44
Iptcaopan 200 mg	Novartis	Phase 3	47
Iptacopan	Novartis	Phase 3	47
MR13A9 + Placebo	Kissei Pharmaceutical	Phase 3	40
MR13A9 + Placebo	Kissei Pharmaceutical	Phase 2	35
CCX168	Amgen	Phase 2	27
Cemdisiran	Alnylam Pharmaceuticals	Phase 2	24
cemdisiran + Placebos	Alnylam Pharmaceuticals	Phase 2	24
nalbuphine HCl ER	Trevi Therapeutics	Phase 2/3	32
Nalbuphine HCL ER	Trevi Therapeutics	Phase 1	23
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BID	Trevi Therapeutics	Phase 2/3	32